This indicates that pharmacological TRAF6 inhibition could be a target to prevent obesity related inflammation and metabolic complications (Lutgens et al., 2010; Chatzigeorgiou et al., 2014). The gene discussed is TRAF6; the disease is obesity due to melanocortin 4 receptor deficiency.